Skip to main content
SUPN
NASDAQ Life Sciences

Supernus Pharmaceuticals Seeks Shareholder Approval for Significant Equity Plan Expansion

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$48
Mkt Cap
$2.764B
52W Low
$29.16
52W High
$59.68
52W Position info
65% above low
Off High info
20% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

SUPN sits 65% above its 52-week low of $29.16.

Summary

Supernus Pharmaceuticals filed its definitive proxy statement, seeking shareholder approval to increase its equity incentive plan by 4 million shares, representing a notable potential dilution for existing shareholders.


Key Events · Corporate Governance and Compliance · SUPN

  • Equity Plan Expansion Proposed

    Shareholders will vote on increasing the 2021 Equity Incentive Plan by 4,000,000 shares, which could result in significant future dilution for existing shareholders.

  • Annual Meeting Agenda Set

    The proxy outlines proposals for the annual meeting on June 18, 2026, including director elections, a non-binding vote on executive compensation, and auditor ratification.

  • Executive Compensation Details

    The filing provides detailed executive compensation data for 2025, noting a CEO pay ratio of 81:1 to the median employee.

  • Financial Performance Context

    This request for additional shares comes as the company reported a substantial net loss for 2025 and has seen significant insider selling activity recently.


Analysis · SUPN · Life Sciences

Supernus Pharmaceuticals has filed its definitive proxy statement for its annual meeting, which includes a proposal to increase the shares available under its 2021 Equity Incentive Plan by 4,000,000 shares. If all authorized shares were issued, this would represent approximately 6.89% potential dilution for existing shareholders based on current outstanding shares. This significant expansion of the equity pool for compensation is notable, especially in the context of the company's reported substantial net loss for 2025 and recent insider selling activity, which collectively contribute to a negative sentiment.

At the time of this filing, SUPN was trading at $48.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $29.16 to $59.68. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SUPN - Latest Insights

SUPN
Aug 03, 2026, 6:56 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $53.88
Real-time Price: $46.84 info
Change: -$7.04 (-13%) info
Market Cap: $2.723B info
SUPN
Aug 03, 2026, 6:46 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $49.00
Real-time Price: $46.84 info
Change: -$2.16 (-4%) info
Market Cap: $2.723B info
SUPN
Aug 03, 2026, 6:43 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $47.51
Real-time Price: $46.84 info
Change: -$0.670 (-1%) info
Market Cap: $2.723B info
SUPN
Aug 03, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $44.21
Real-time Price: $46.84 info
Change: +$2.63 (+6%) info
Market Cap: $2.723B info
SUPN
Jun 18, 2026, 4:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $44.38
Real-time Price: $46.84 info
Change: +$2.46 (+6%) info
Market Cap: $2.723B info